Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/19/2021 02/22/2021 02/23/2021 02/24/2021 02/25/2021 Date
64.37(c) 64.11(c) 63.68(c) 63.71(c) 62.79 Last
6 054 624 6 597 733 8 714 604 6 533 104 7 678 172 Volume
-1.32% -0.40% -0.67% +0.05% -1.44% Change
More quotes
Financials (USD)
Sales 2020 24 482 M - -
Net income 2020 137 M - -
Net Debt 2020 24 797 M - -
P/E ratio 2020 534x
Yield 2020 4,25%
Sales 2021 24 857 M - -
Net income 2021 7 236 M - -
Net Debt 2021 17 538 M - -
P/E ratio 2021 11,8x
Yield 2021 4,43%
Capitalization 78 709 M 78 709 M -
EV / Sales 2020 4,23x
EV / Sales 2021 3,87x
Nbr of Employees 11 800
Free-Float 99,9%
More Financials
Company
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.5%): especially royalties and... 
Sector
Biotechnology & Medical Research
Calendar
02/25 | 01:40pmPresentation
More about the company
Notations Surperformance© of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about GILEAD SCIENCES, INC.
04:20pGILEAD SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
02/23GILEAD SCIENCES : EU drugs regulator studying expanded use of COVID-19 drug remd..
RE
02/18GILEAD SCIENCES : to Present at Upcoming Investor Conferences
BU
02/17Waiting for Big Pharma's Coronavirus Profits to Impress Wall Street -- Heard ..
DJ
02/16GILEAD SCIENCES : and Wake Forest University School of Divinity Partner to Addre..
BU
02/16SUPREME COURT DECLINES TO HEAR IDENI : Dispute Surrounding The Enablement Standa..
AQ
02/11INSIDER TRENDS : Gilead Sciences Insider Sale Scales Back 90-Days of Buys
MT
02/11GILEAD SCIENCES : SVB Leerink Adjusts Gilead Sciences' Price Target to $72 From ..
MT
02/11GILEAD SCIENCES : Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylac..
AQ
02/10GILEAD SCIENCES : Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylac..
BU
02/10GILEAD SCIENCES : Galapagos Halted Lung Disease Drug Candidate Expected to Accou..
MT
02/10European shares track Wall Street's dip into the red
RE
02/10GALAPAGOS : Gilead Suspends Late-Stage Trials of Pulmonary Fibrosis Therapeutic
MT
02/10GILEAD SCIENCES : Galapagos Halt Trial of Pulmonary-Fibrosis Treatment
DJ
02/10GILEAD SCIENCES, INC. : Report
CO
More news
News in other languages on GILEAD SCIENCES, INC.
02/23WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
02/23CORONAVIRUS : L'EMA va évaluer d'ici l'été un usage étendu du remdesivir
02/23El regulador de medicamentos de la UE estudia ampliar el uso del remdesivir a..
02/12Roche poursuit l'évaluation de l'Actemra contre la Covid-19
02/12Los problemas renales de los pacientes de COVID-19 no están relacionados con ..
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 74,00 $
Last Close Price 63,71 $
Spread / Highest target 57,0%
Spread / Average Target 16,2%
Spread / Lowest Target -7,39%
EPS Revisions
Managers and Directors
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.7.78%79 862
VERTEX PHARMACEUTICALS-8.17%56 422
WUXI APPTEC CO., LTD.9.26%55 903
REGENERON PHARMACEUTICALS-3.12%47 761
BEIGENE, LTD.29.61%30 633
BIONTECH SE40.05%27 490